FDA Seizure Of Paxil CR, Avandamet Follows GSK's Failure To Recall All Lots
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's February recall involving the two drugs did not encompass all affected lots, FDA says in announcing seizure of all doses and lots of the products. The action follows two "Form 483" reports in the last two years for GSK's Cidra, Puerto Rico facility, where the antidepressant and antidiabetic drugs are manufactured.
You may also be interested in...
Why Baxter’s GMP False Claims Settlement Was Smaller Than Those Of GSK, Ranbaxy
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.
Ripping The Bandage Off: GSK Resolves Suits On Many Products For $2.3 Bil.
GlaxoSmithKline's decision to resolve its most onerous litigation in one fell swoop put it among the largest payouts by a pharma company
Ripping The Bandage Off: GSK Resolves Suits On Many Products For $2.3 Bil.
GlaxoSmithKline's decision to resolve its most onerous litigation in one fell swoop put it among the largest payouts by a pharma company